# ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

> **NCT05878860** · PHASE3 · RECRUITING · sponsor: **Atsena Therapeutics Inc.** · enrollment: 97 (estimated)

## Conditions studied

- X-linked Retinoschisis

## Interventions

- **BIOLOGICAL:** ATSN-201

## Key facts

- **NCT ID:** NCT05878860
- **Lead sponsor:** Atsena Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-22
- **Primary completion:** 2028-04
- **Final completion:** 2033-04
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05878860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05878860, "ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05878860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*